Chenglei Zhang

Dr. Chenglei Zhang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2025 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
JWJingtao Wang
Jingtao Wang
QZQidong Zhang
Qidong Zhang
WFWu Fan
Wu Fan
QSQingzhao Shi
Qingzhao Shi
JMJian Mao
Jian Mao
CZChenglei Zhang
Chenglei Zhang
Olfactory receptors, classified as G-protein coupled receptors (GPCRs), have been a subject of scientific inquiry since the early 1950s. Historically, investigations into the sensory mechanisms of olfactory receptors were often confined to behavioral characteristics in model organisms or the expression of related proteins and genes. However, with the development of cryo-electron microscopy techniques, it has gradually become possible to decipher the specific structures of olfactory receptors in insects and humans. This has provided new insights into the binding mechanisms between odor molecules and olfactory receptors. Furthermore, due to the rapid advancements in related fields such as computer simulations, the prediction and exploration of odor molecule binding to olfactory receptors have been progressively achieved through molecular dynamics simulations. Through this comprehensive review, we aim to provide a thorough analysis of research related to the binding mechanisms between odor molecules and olfactory receptors from the perspectives of structural biology and molecular dynamics simulations. Finally, we will provide an outlook on the future of research in the field of olfactory receptor sensory mechanisms.

16 October 2024 in Cell Proliferation
Verified
Journal Article
Open access
CZChenglei Zhang
Chenglei Zhang
JLJiarui Li
Jiarui Li
LWLijuan Wang
Lijuan Wang
JMJie Ma
Jie Ma
XLXin Li
Xin Li
YYYi Yang
Yi Yang
GPR119 agonists are being developed to safeguard the function of pancreatic β‐cells, especially in the context of non‐alcoholic fatty pancreas disease (NAFPD) that is closely associated with β‐cell dysfunction. This study aims to employ a drug repurposing strategy to screen GPR119 agonists and explore their potential molecular mechanisms for enhancing β‐cell function in the context of NAFPD. MIN6 cells were stimulated with palmitic acid (PA), and a NAFPD model was established in GPR119−/− mice fed with a high‐fat diet (HFD). Terazosin, identified through screening, was utilized to assess its impact on enhancing β‐cell function via the MST1‐Foxo3a pathway and mitophagy. Terazosin selectively activated GPR119, leading to increased cAMP and ATP synthesis, consequently enhancing insulin secretion. Terazosin administration improved high blood glucose, obesity, and impaired pancreatic β‐cell function in NAFPD mice. It inhibited the upregulation of MST1‐Foxo3a expression in pancreatic tissue and enhanced damaged mitophagy clearance, restoring autophagic flux, and improving mitochondrial quantity and structure in β‐cells. Nevertheless, GPR119 deficiency negated the positive impact of terazosin on pancreatic β‐cell function in NAFPD mice and abolished its inhibitory effect on the MST1‐Foxo3a pathway. Terazosin activates GPR119 on the surface of pancreatic β‐cells, enhancing mitophagy and alleviating β‐cell dysfunction in the context of NAFPD by suppressing the MST1‐Foxo3a signalling pathway. Terazosin could be considered a priority treatment for patients with concomitant NAFPD and hypertension.

17 June 2023 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Open access
JWJing-Jiao Wang
Jing-Jiao Wang
CZChenglei Zhang
Chenglei Zhang
XGXiao-Qian Guo
Xiao-Qian Guo
CYChang-Yi Yang
Chang-Yi Yang
Periodontitis is a chronic inflammatory disease caused by Porphyromonas gingivalis and other bacteria, and human periodontal ligament stem cells (hPDLSCs) are a promising candidate for the treatment of periodontal supporting tissue defects. This study aimed to investigate the effect of 1α,25-dihydroxyvitamin D3 [1,25(OH)2VitD3] on osteogenic differentiation of hPDLSCs in an in vitro periodontitis model and whether it can improve inflammatory status. hPDLSCs were in vitro isolated and identified. After treatment with 1,25(OH)2VitD3 and ultrapure pure Porphyromonas gingivalis lipopolysaccharide (LPS-G), the viability of hPDLSCs was detected using Cell Counting Kit-8, the expressions of osteogenic markers and inflammatory genes using Western blotting and quantitative reverse transcription PCR (qRT-PCR), the levels of inflammatory factors in cells using enzyme linked immunosorbent assay (ELISA), and the fluorescence signal intensity of osteoblastic markers and inflammatory genes in cells using immunofluorescence assay. It was found that 1,25(OH)2VitD3 reversed the inhibition of hPDLSCs proliferation by LPS-G; LPS-G exhibited inhibitory effect on ALP, Runx2, and OPN expressions, and such inhibitory effect was significantly weakened when co-acting with 1,25(OH)2VitD3. Meanwhile, LPS-G upregulated the expressions of inflammatory genes IL-1β and Casp1, whereas 1,25(OH)2VitD3 antagonized such an effect and improved the inflammatory status. In conclusion, 1,25(OH)2VitD3 can reverse the inhibitory effect of LPS-G on hPDLSCs proliferation and osteogenic differentiation and suppress LPS-G-induced upregulation of inflammatory gene expressions.

17 April 2025 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
LWLijuan Wang
Lijuan Wang
CZChenglei Zhang
Chenglei Zhang
JMJie Ma
Jie Ma
JLJiarui Li
Jiarui Li
YWYuanyuan Wu
Yuanyuan Wu
YYYi Yang
Yi Yang
Background: Non-alcoholic steatohepatitis (NASH) progression is strongly associated with deteriorating hepatic function, primarily driven by free cholesterol (FC) accumulation-induced lipotoxicity. Emerging evidence highlights the regulatory role of mammalian Ste20-like kinase 1 (MST1) in modulating intrahepatic lipid homeostasis, suggesting its therapeutic potential for non-alcoholic fatty liver disease (NAFLD) management. This investigation seeks to elucidate the pathophysiological mechanisms through which MST1 modulates NASH progression. Methods: The experimental design employed two murine genetic models—wild-type (WT) controls and MST1-knockout (MST1-KO) specimens—subjected to a nutritionally modified Western diet (WD) enriched with saturated fats, simple carbohydrates, and dietary cholesterol to induce non-alcoholic steatohepatitis (NASH) pathogenesis. Lentiviral transduction techniques facilitated targeted MST1 overexpression in WT animals maintained on this dietary regimen. Parallel in vitro investigations utilized HepG2 hepatocyte cultures exposed to free fatty acid (FFA) cocktails comprising palmitic and oleic acids, coupled with CRISPR-mediated MST1 suppression and complementary gain-of-function manipulations to delineate molecular mechanisms. Results: NASH triggers hepatic sterol biosynthesis activation, resulting in pathological FC overload concurrent with MST1 transcriptional suppression. Genetic ablation of MST1 amplifies intrahepatic FC retention and potentiates histopathological inflammation, while MST1 reconstitution mitigates steatotic FC deposition and attenuates inflammatory cascades. Mechanistic profiling revealed MST1-mediated AMPKα phosphorylation at Thr172, which suppresses cholesterogenic enzyme expression via sterol regulatory element-binding transcription factor 2 (SREBP2) axis modulation. This phosphorylation cascade demonstrates dose-dependent inhibition of HMGCR activity, resolving FC-induced hepatotoxicity. Crucially, MST1 orchestrates AMPK/SREBP2 crosstalk to maintain sterol homeostasis, with knockout models exhibiting 67% elevated SREBP2 nuclear translocation compared to controls. Conclusions: The regulatory axis involving MST1-mediated AMPK phosphorylation emerges as a promising therapeutic modality for modulating hepatic sterol metabolism. It demonstrates significant potential in arresting the progression of inflammatory cascades and extracellular matrix remodeling characteristic of NASH pathogenesis. Mechanistic studies confirm that this phosphorylation cascade effectively suppresses de novo lipogenesis while enhancing cholesterol efflux capacity, thereby establishing a dual-target strategy against both metabolic dysfunction and fibrotic transformation in preclinical models.

1 January 2023 in Cell Transplantation
Verified
Journal Article
Open access
JWJingjiao Wang
Jingjiao Wang
SGSonglin Guo
Songlin Guo
XXXiaobo Xu
Xiaobo Xu
CZChenglei Zhang
Chenglei Zhang
This study aims to investigate the effects of 1,25-dihydroxyvitamin D3 (1,25(OH)2VitD3) on osteogenic differentiation of human periodontal ligament stem cells (hPDLSCs) and the activity of hPDLSC sheets and the differences in the tissue regeneration activity of hPDLSC sheets on tooth root fragment treated by different methods. Healthy caries-free premolars were collected. The hPDLSCs were obtained by enzymatic digestion. Surface markers of stem cells were analyzed by flow cytometry and the multidirectional differentiation ability of hPDLSCs was detected. During the osteogenic differentiation of hPDLSCs, 1,25(OH)2VitD3 was added and the effect of 1,25(OH)2VitD3 on osteogenic differentiation of hPDLSCs was assessed using Western blotting, quantitative reverse transcription–polymerase chain reaction (qRT-PCR), enzyme-linked immunosorbent assay, cell staining, and immunofluorescence. After hPDLSC sheets were prepared, histology and immunofluorescence analysis of the effect of 1,25(OH)2VitD3 on sheet activity were performed. In addition, root fragments were prepared and treated with scaling, 24% EDTA (ethylenediamide tetraacetic acid), and Er,Cr:YSGG lasers, respectively, and the tissue regeneration activity of hPDLSC sheets on different root fragments were observed. 1,25(OH)2VitD3 promoted the high gene and protein expressions of osteogenic markers ALP (alkaline phosphatase), Runx2, and OPN (osteopontin antibody) in hPDLSCs, along with enhanced ALP activity and staining, alizarin red staining, and immunofluorescence staining, indicating that the osteogenic differentiation ability of hPDLSCs was improved. Extracellular matrix secretion was increased in hPDLSC sheets, along with the positive expressions of the protein markers fibronectin and collagen I, suggesting that 1,25(OH)2VitD3 could enhance these effects. In addition, the root fragments treated by Er,Cr:YSGG laser were more suitable for the attachment and regeneration of hPDLSC sheets, demonstrating that 1,25(OH)2VitD3 could improve the tissue regeneration performance of these sheets. 1,25(OH)2VitD3 can promote osteogenic differentiation of hPDLSCs and thus plays an active role in hPDLSC sheet formation and tissue regeneration. In addition, the Er,Cr:YSGG laser can be used as the recommended treatment method for the root surface regenerated by hPDLSCs.

14 March 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
XWXu Wang
Xu Wang
HLHaibin Lu
Haibin Lu
JXJing Xie
Jing Xie
CZChenglei Zhang
Chenglei Zhang
Carotid artery stenosis is a manifestation of atherosclerosis and is associated with an increased risk of various cardiovascular diseases. Clopidogrel is an antiplatelet drug widely used for the prevention and treatment of atherosclerosis-related diseases. This study explores the potential molecular mechanisms of clopidogrel in the treatment of carotid artery stenosis through network pharmacology and molecular docking techniques. First, network pharmacology methods were used to construct a clopidogrel target network and identify its possible 127 action targets. Secondly, the gene ontology enrichment analysis indicated that clopidogrel for treating carotid stenosis is closely related to inflammatory responses, platelet activation, and angiogenesis. The Kyoto Encyclopedia of Genes and Genomes analysis revealed associations with lipid metabolism and atherosclerosis. Subsequently, molecular docking technology was employed to screen the binding affinity of clopidogrel to these targets. The results revealed that clopidogrel exhibited binding energies less than − 4.20 kcal/mol with multiple targets, including TNF, MMP9, PTGS2, CCL2, TLR4, and IL-10. This indicates that clopidogrel has high binding affinity and stable binding modes with these targets, thereby exerting anti-inflammatory effects. This study reveals the potential molecular mechanisms of clopidogrel in the treatment of carotid artery stenosis through network pharmacology and molecular docking techniques. The experimental results provide a theoretical basis for the application of clopidogrel in the treatment of carotid artery stenosis and offer new ideas for further drug development and personalized treatment.